- Duloxetine 120 mg was the most cost-effective option.
- Pregabalin 450 mg was favorable only when societal costs were included.
- Lower doses and milnacipran were less effective and more costly.
- Dose matters—duloxetine 120 mg outperformed 60 mg.
- Results showed notable uncertainty across models.
Source: JAMA Network Open
